Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
about
Suicidal behavior and depression in smoking cessation treatmentsEfficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studiesRegulation of glucose homeostasis by GLP-1Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studiesMarked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumorsThe Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic CancerAdvances in the treatment of type 2 diabetes: impact of dulaglutideIncretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitorsExenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectivesAdverse Effects of GLP-1 Receptor AgonistsDiabetes and cancer: two diseases with obesity as a common risk factorIncretin based therapies: a novel treatment approach for non-alcoholic fatty liver diseaseSafety of dipeptidyl peptidase 4 inhibitors: a perspective reviewBasal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingSystematic reviews to ascertain the safety of diabetes medicationsTherapy for obesity based on gastrointestinal hormonesUse of glucagon-like peptide-1 agonists to improve islet graft performanceAction and therapeutic potential of oxyntomodulinGlucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesManagement of pancreatogenic diabetes: challenges and solutionsRecent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical TrialsAlogliptin benzoate for management of type 2 diabetesDipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trialsImpact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control studyType 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implicationsRational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms.Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.Exendin-4 induces cell adhesion and differentiation and counteracts the invasive potential of human neuroblastoma cellsSafety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.Latest insights into the risk of cancer in diabetesCancer biology in diabetes.Diabetes medications and cancer risk: review of the literatureOnce-weekly albiglutide in the management of type 2 diabetes: patient considerations.GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?
P2860
Q21089921-2F1FB011-BD28-4178-BA81-F85E287EE2D3Q24288949-5A866421-2AB2-46DA-A97F-CF5FE3865A81Q24563430-F4FAC3BE-E46D-4FE0-9F76-AFAB65A1579AQ24568148-3EE6460B-3949-4E12-A0F2-3B6E21AC20BEQ24598747-3C8B3655-DB78-4932-9931-48B6BDB815A6Q26738873-97C50E57-20D8-4841-9E4F-BC54363FA1EBQ26746220-F463A8B9-4570-4B63-B697-492A54966FF8Q26778608-CCA2E39A-495C-4D7B-B7D5-D82E0026DFA3Q26797236-C0E9E3B2-B1A9-445F-958E-43F149D139FFQ26801346-FC07C872-254E-4446-863D-78B1CF05C692Q26822753-38E68414-742A-4F59-8F6B-14AC83600120Q26827183-690CD5F7-DBAD-4057-9C8F-9DC4E92B82BFQ26863262-AFC89496-E6E4-4C36-BF01-A3BB59AA82A5Q26992979-E21BF9DF-E8F4-4C0D-BC61-94FD1189470EQ27000766-C4FADE37-CE9F-4044-9A06-76F75BFAE456Q27006777-EEA452DC-E20C-4637-9328-3FFC340402A7Q27013927-C1571CE8-91E7-48D5-9186-E78C23C11AF7Q27025870-67113B07-E85A-4B2D-BE58-CA39ADCAAACBQ28067465-B6FAF42A-E304-4F8D-B046-058D84BEC372Q28069386-03306379-9F36-4AD9-9CF0-C54AAC69641CQ28081569-1035A3D1-5669-41EA-8894-FE009D3F90FAQ28083933-14968BD8-497A-4DC6-A993-76C93673BADCQ28294225-19299BA4-B2DC-4C59-8646-3D5782A1B178Q28535372-FD7C6F71-4EDE-4C62-B347-8790E93C440BQ30234827-ED8F4C4C-621E-4645-9399-E5FB4CFFF027Q30239808-9A5A8BBA-093B-4501-9F94-8CF0074C6021Q30410721-583B55DC-E13F-4324-B341-CEAB4F0F96C3Q30513617-6F8893B5-72C4-4F1D-83AA-4315CFC91554Q30597265-ED60A827-CBAB-422F-B9B1-24DBD1924265Q30643065-4F80615E-E095-4B5E-8516-921D89B32D9DQ30848457-3BE26730-7EDC-4C1B-B738-9ADCBBA44522Q30856973-50F5327E-FD4A-4AFF-961F-E69E4006B107Q31066859-43A72AA6-5D8D-4B5E-B9F8-E1D413405C3EQ31131659-CEEF5063-17C5-44C7-8770-89BD96CB560FQ31167862-CA7F48F4-55B4-4C4F-8667-ECE734FFF795Q33588852-F0B0E22B-AD77-4268-99F3-A97182BAC3DDQ33608038-4DA362D8-3D31-4666-ADE9-E12D63087F05Q33714881-D1CF0D5A-298D-4C40-9D90-F249DE3F2BF8Q33728226-7F0203F2-9108-43B9-AEF4-BFFDCF33D4A5Q33734024-05F87359-3D24-4AA2-B444-361E4C68827D
P2860
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
@ast
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
@en
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
@nl
type
label
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
@ast
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
@en
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
@nl
prefLabel
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
@ast
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
@en
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
@nl
P2093
P2860
P1433
P1476
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
@en
P2093
Aleksey V Matveyenko
Belinda Gier
Peter C Butler
P2860
P304
P356
10.1053/J.GASTRO.2011.02.018
P407
P577
2011-02-18T00:00:00Z